Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer

Endocrine-Related Cancer

Volumn 22, Issue 3, 2015, Pages 319-329

  Mehta, Amit ^a,b   Zhang, Lisa ^a   Boufraqech, Myriem ^a   Zhang, Yaqin ^c   Patel, Dhaval ^a   Shen, Min ^c   Kebebew, Electron ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Anaplastic thyroid cancer; Carfilzomib; High throughput screening; Proteasome inhibitor

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; APOPTOSIS REGULATORY PROTEIN; BORTEZOMIB; CARFILZOMIB; CASPASE; DOCETAXEL; DOXORUBICIN; NERVE CELL ADHESION MOLECULE; PROTEIN P21; PROTEIN P27; PROTEIN P53; VIMENTIN; ANTINEOPLASTIC AGENT; OLIGOPEPTIDE;

ANAPLASTIC THYROID CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE ASSAY; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DIARRHEA; DISTANT METASTASIS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SCREENING; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GASTROINTESTINAL SYMPTOM; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY METASTASIS; LIVER METASTASIS; LOSS OF APPETITE; LUNG METASTASIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; RECURRENT DISEASE; THYROID CANCER CELL LINE; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETIC TRANSFECTION; NONOBESE DIABETIC MOUSE; PATHOLOGY; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; MICE, INBRED NOD; OLIGOPEPTIDES; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; TRANSFECTION;

EID: 84937029829     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0510     Document Type: Article

References (43)

1. Adams J 2004 The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5 417-421. (doi:10.1016/S1535-6108(04)00120-5)
2. Ain KB 1998 Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8 715-726. (doi:10.1089/thy.1998.8.715)
3. Altmann A, Markert A, Askoxylakis V, Schoning T, Jesenofsky R, EisenhutM & Haberkorn U 2012 Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma. Journal of NuclearMedicine 53 1764-1771. (doi:10.2967/jnumed.111.101295)
4. Ameri K & Harris AL 2008 Activating transcription factor 4. International Journal of Biochemistry & Cell Biology 40 14-21. (doi:10.1016/j.biocel.2007.01.020)
5. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M & Bonavida B 2009 Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene 28 3573-3585. (doi:10.1038/onc.2009.214)
6. Besic N & Gazic B 2013 Sites of metastases of anaplastic thyroid carcinoma: autopsy findings in 45 cases from a single institution. Thyroid 23 709-713. (doi:10.1089/thy.2012.0252)
7. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L et al. 1997 Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nature Medicine 3 227-230. (doi:10.1038/nm0297-227)
8. Chaffer CL & Weinberg RA 2011 A perspective on cancer cell metastasis. Science 331 1559-1564. (doi:10.1126/science.1203543)
9. Conticello C, Adamo L, Giuffrida R, Vicari L, Zeuner A, Eramo A, Anastasi G, Memeo L, Giuffrida D, Iannolo G et al. 2007 Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. Journal of Clinical Endocrinology and Metabolism 92 1938-1942. (doi:10.1210/jc.2006-2157)
10. Cuadrado M, Gutierrez-Martinez P, Swat A, Nebreda AR & Fernandez-Capetillo O 2009 p27Kip1 stabilization is essential for the maintenance of cell cycle arrest in response to DNA damage. Cancer Research 69 8726-8732. (doi:10.1158/0008-5472.CAN-09-0729)
11. Demo SD, KirkCJ, AujayMA, Buchholz TJ, DajeeM, HoMN, JiangJ, Laidig GJ, Lewis ER, Parlati F et al. 2007 Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Research 67 6383-6391. (doi:10.1158/0008-5472.CAN-06-4086)
12. Granata R, Locati L & Licitra L 2013 Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature. Current Opinion in Oncology 25 224-228. (doi:10.1097/CCO.0b013e32835ff44b)
13. Groll M, Huber R & Potts BC 2006 Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of b-lactone ring opening and a mechanism for irreversible binding. Journal of the American Chemical Society 128 5136-5141. (doi:10.1021/ja058320b)
14. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J & Anderson KC 2001 The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research 61 3071-3076.
15. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et al. (eds) 2013. SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
16. Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, Nguyen DT & Austin CP 2011 The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Science Translational Medicine 3 80ps16. (doi:10.1126/scitranslmed.3001862)
17. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, Zheng W & Austin CP 2006 Quantitative high-throughput screening: a titrationbased approach that efficiently identifies biological activities in large chemical libraries. PNAS 103 11473-11478. (doi:10.1073/pnas.0604348103)
18. Jain S, Diefenbach C, Zain J & O'Connor OA 2011 Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. Core Evidence 6 43-57. (doi:10.2147/CE.S13838)
19. Jiang Q, Li F, Shi K, Wu P, An J, Yang Y & Xu C 2013 ATF4 activation by the p38MAPK-eIF4E axis mediates apoptosis and autophagy induced by selenite in Jurkat cells. FEBS Letters 587 2420-2429. (doi:10.1016/j.febslet.2013.06.011)
20. Kebebew E, Greenspan FS, Clark OH, Woeber KA & McMillan A 2005 Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103 1330-1335. (doi:10.1002/cncr.20936)
21. Kim JY, Nam JK, Lee SA, Lee MS, Cho SK, Park ZY, Lee JW & Cho M 2011 Proteasome inhibition causes epithelial-mesenchymal transition upon TM4SF5 expression. Journal of Cellular Biochemistry 112 782-792. (doi:10.1002/jcb.22954)
22. Kudo Y, Takata T, Ogawa I, Kaneda T, Sato S, Takekoshi T, Zhao M, Miyauchi M & Nikai H 2000 p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clinical Cancer Research 6 916-923.
23. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM & Pagano M 1997 Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Medicine 3 231-234. (doi:10.1038/nm0297-231)
24. Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D & Harris AL 2009 The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Research 69 4415-4423. (doi:10.1158/0008-5472.CAN-08-2839)
25. Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P, Van Leer D, Leister W, Austin CP & Xia M 2014 Identification of known drugs that act as inhibitors of NF-kB signaling and their mechanism of action. Biochemical Pharmacology 79 1272-1280. (doi:10.1016/j.bcp.2009.12.021)
26. Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB & Mitsiades N 2006 Antitumor effects of the proteasome inhibitor bortezomib inmedullary and anaplastic thyroid carcinoma cells in vitro. Journal of Clinical Endocrinology and Metabolism 91 4013-4021. (doi:10.1210/jc.2005-2472)
27. Munos B 2009 Lessons from 60 years of pharmaceutical innovation. Nature Reviews. Drug Discovery 8 959-968. (doi:10.1038/nrd2961)
28. Nagaiah G, Hossain A, Mooney CJ, Parmentier J & Remick SC 2011 Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. Journal of Oncology 2011 542358. (doi:10.1155/2011/542358)
29. Nilubol N, Zhang L, Shen M, Zhang YQ, He M, Austin CP & Kebebew E 2012 Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening. Journal of Translational Medicine 10 198. (doi:10.1186/1479-5876-10-198)
30. O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF & Orlowski RZ 2009 A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clinical Cancer Research 15 7085-7091. (doi:10.1158/1078-0432.CCR-09-0822)
31. PapandreouCN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L et al. 2004 Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. Journal of Clinical Oncology 22 2108-2121. (doi:10.1200/JCO.2004.02.106)
32. Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, Micklem DR, Ruurs P, Sylvain C, Lu Y et al. 2009 Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114 3439-3447. (doi:10.1182/blood-2009-05-223677)
33. Ruckrich T, Kraus M, Gogel J, Beck A, Ovaa H, Verdoes M, Overkleeft HS, Kalbacher H & Driessen C 2009 Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia 23 1098-1105. (doi:10.1038/leu.2009.8)
34. Rzymski T, Milani M, Singleton DC & Harris AL 2009 Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle 8 3838-3847. (doi:10.4161/cc.8.23.10086)
35. Shahinas D, Liang M, Datti A & Pillai DR 2010 A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90. Journal of Medicinal Chemistry 53 3552-3557. (doi:10.1021/jm901796s)
36. Shum D, Smith JL, Hirsch AJ, Bhinder B, Radu C, Stein DA, Nelson JA, Fruh K & Djaballah H 2010 High-content assay to identify inhibitors of dengue virus infection. Assay and Drug Development Technologies 8 553-570. (doi:10.1089/adt.2010.0321)
37. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS et al. 2012 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22 1104-1139. (doi:10.1089/thy.2012.0302)
38. Voorhees PM, Dees EC, O'Neil B & Orlowski RZ 2003 The proteasome as a target for cancer therapy. Clinical Cancer Research 9 6316-6325.
39. Wang X, Gorospe M, Huang Y & Holbrook NJ 1997 p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene 15 2991-2997. (doi:10.1038/sj.onc.1201450)
40. Wunderlich A, Arndt T, Fischer M, Roth S, Ramaswamy A, Greene BH, Brendel C, Hinterseher U, Bartsch DK & Hoffmann S 2012 Targeting the proteasome as a promising therapeutic strategy in thyroid cancer. Journal of Surgical Oncology 105 357-364. (doi:10.1002/jso.22113)
41. YasuiW, Kudo Y, Semba S, Yokozaki H & Tahara E 1997 Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associatedwith advanced stage and invasiveness of gastric carcinomas. Japanese Journal of Cancer Research 88 625-629. (doi:10.1111/j.1349-7006.1997.tb00428.x)
42. Zhang L, He M, Zhang Y, Nilubol N, Shen M & Kebebew E 2012 Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing. Journal of Clinical Endocrinology and Metabolism 97 E319-E328. (doi:10.1210/jc.2011-2671)
43. Zhang L, Gaskins K, Yu Z, Xiong Y, MerinoMJ & Kebebew E 2014 An in vivo mouse model of metastatic human thyroid cancer. Thyroid 24 695-704. (doi:10.1089/thy.2013.0149)